Publicación:
Does the use of cysteine-rich whey protein supplements (Inmunocal®) improve the health well-being of COVID-19 patients? A qualitative study

dc.contributor.authorContreras-Pulache, Hans
dc.contributor.authorCañari Ccoica, Betsy Jasmit
dc.contributor.authorMoya Salazar, Jeel Junior
dc.contributor.authorContreras Pulache, Hans Lenin
dc.date.accessioned2025-09-05T16:34:19Z
dc.description.abstractIntroduction: In the context of SARS-CoV-2 infection, it has been proposed that oxidative stress may contribute to the management of COVID-19 severity. The impact on the well-being of patients with COVID-19 using cysteine-providing supplements has not yet been evaluated and there is a need to understand the benefits and limitations they may offer. Aim: The aim of this study is to understand the experiences of improved well-being with cysteine-rich whey protein supplementation (Immunocal®) in patients with COVID-19. Methods: A qualitative study was conducted by conducting semi-structured interviews with four participants taking Immunocal® while they had COVID-19. Participants were randomly recruited through internet networking. Ethical approval was obtained from the University ethics committee. Participants were informed of the study objectives two days in advance and consent was obtained before interviews began. We used the 16-item “Use of Immunocal supplement for COVID-19” (USIC-19) questionnaire to inquire about COVID-19 behavior (time of illness, symptoms, and severity of illness) and the experience of using the supplement during illness. Confidentiality was maintained throughout this study. Results: All participants presented mild discomfort such as headache, weakness, and tiredness when they had COVID-19 impacting most of them emotionally. The use of Immunocal® produced a partial improvement in all patients as only two continued to experience fatigue. Immunocal® improved the mood (50%) and physical health of the participants. In addition, participants reported that the supplement was recommended and dosed primarily by a consultant and that they did not feel hesitant to use it because of previous experiences of friends and family. The daily dosage of half of the participants was two sachets and all felt the need to consume the supplement which resulted in daily use. Conclusion: Following the daily dosage indications of the consultants, the participants who have consumed Inmunocal® have presented a partial improvement of the symptoms related to COVID-19, however, they feel the need to consume the supplement daily to improve their quality of life. © 2023 Elsevier B.V., All rights reserved.
dc.identifier.doi10.29333/ejgm/12652
dc.identifier.scopus2-s2.0-85145566949
dc.identifier.urihttps://cris.uwiener.edu.pe/handle/001/444
dc.identifier.uuid79495fef-d6fb-440c-bf12-a2980d77a70d
dc.language.isoen
dc.publisherModestum LTD
dc.relation.citationissue1
dc.relation.citationvolume20
dc.relation.ispartofseriesElectronic Journal of General Medicine
dc.relation.issn25163507
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.titleDoes the use of cysteine-rich whey protein supplements (Inmunocal®) improve the health well-being of COVID-19 patients? A qualitative study
dc.typehttp://purl.org/coar/resource_type/c_2df8fbb1
dspace.entity.typePublication
organization.acronymUPNW
organization.acronymUPNW
organization.acronymUPNW
organization.identifier.ruc20466246370
organization.identifier.ruc20466246370
organization.identifier.ruc20466246370
organization.identifier.uuidbc9cd13b-f0cb-4129-9e1e-12af4a868e0c
organization.identifier.uuidbc9cd13b-f0cb-4129-9e1e-12af4a868e0c
organization.identifier.uuidbc9cd13b-f0cb-4129-9e1e-12af4a868e0c
person.affiliation.nameUniversidad Privada Norbert Wiener
person.affiliation.nameUniversidad Privada Norbert Wiener
person.affiliation.nameUniversidad Privada Norbert Wiener
person.identifier.orcid0000-0002-4526-0848
person.identifier.orcid0000-0002-7357-4940
person.identifier.orcid0000-0003-2450-9349
person.identifier.uuid4320744e-4ba1-4044-a1a0-5c758b4d2198
person.identifier.uuid55dc56b0-1652-4a5e-9dc6-25b9d6d82e6d
person.identifier.uuid69e40673-af6f-497d-abf4-bc9c7ab43d4b
relation.isAuthorOfPublication4320744e-4ba1-4044-a1a0-5c758b4d2198
relation.isAuthorOfPublication55dc56b0-1652-4a5e-9dc6-25b9d6d82e6d
relation.isAuthorOfPublication69e40673-af6f-497d-abf4-bc9c7ab43d4b
relation.isAuthorOfPublication.latestForDiscovery4320744e-4ba1-4044-a1a0-5c758b4d2198

Archivos

Colecciones